VCIP135 Antibody 88153S from Cell Signaling Technology

Published Figures

Register or Sign In to View Figures.

Signal transduction and targeted therapy
June 22 2022

Fig 1: MATIIα and VCIP135 are upregulated in HCC and significantly associated with poor prognosis. a VCIP135 and MATIIα protein levels were detected by immunoblotting from HCC cell lines. b Represent images of IHC staining with antibodies against MATIIα or VCIP135 from human HCC patients (n = 58). c, d Quantification of MATIIα (c) and VCIP135 (d) protein levels according to IHC scores in HCC (n = 58). Adj, adjacent; Can, Cancer. Median indicated as dotted lines, two-tailed t-test. e Positive correlation of VCIP135 with MATIIα protein levels determined by IHC staining. The 58 samples were classified into two groups (High VCIP135, 51; Low VCIP135, 7) based on the VCIP135 level. f Positive correlation of VCIP135 with MATIIα protein levels in human hepatocellular cancer tissues samples. VCIP135 and MAT2A protein expression were detected by immunoblotting (n = 21). Spearman correlation, two-tailed. g Kaplan–Meier survival curves for patients with high VCIP135 expression have poorer overall survival compared with patients with low VCIP135 expression in liver cancer. Cutoff value used in analysis is 706. Log-rank (Mantel-Cox) test. FA, folic acid. h Levels of one-carbon metabolites from paired HCCs and non-tumor liver tissues of patients, (n = 44 per group). Median indicated as dotted lines, two-tailed t-test. i, j Different one-carbon metabolism-related genes expression levels in patients (TCGA, i and GSE14520, j). Median indicated as dotted lines, two-tailed t-test. k Working model. Higher folate diet enhances while folate free diet attenuates HCC development. Data in a is representative of three independent experiments. n.s. donates for no significance, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001
Register or Sign In to View Figures.

Signal transduction and targeted therapy
June 22 2022

Fig 2: MATIIα and VCIP135 are essential for HCC proliferation.a, b Quantification of different metabolites of VCIP135 knockdown in MHCC-97H cells (a) and MHCC-LM3 cells (b). Mean ± s.e.m. of n = 3 biologically independent experiments, one-way ANOVA test. c, d Quantification of different metabolites of MAT2A knockdown in MHCC-97H cells (c) and MHCC-LM3 cells (d). Mean ± s.e.m. of n = 3 biologically independent experiments, one-way ANOVA test. e VCIP135 putback recovers VCIP135 knockdown-induced reduction of cell proliferation in MHCC-LM3 cells. Mean ± s.e.m. of n = 3 biologically independent experiments, one-way ANOVA test. f MAT2A putback recovers VCIP135 knockdown-induced reduction of cell proliferation in MHCC-LM3 cells in normal medium. Mean ± s.e.m. of n = 3 biologically independent experiments, one-way ANOVA test. g The effects of MAT2A and VCIP135 double knockdown on proliferation in vitro. Mean ± s.e.m. of n = 3 biologically independent experiments, one-way ANOVA test. h MTX and FIDAS-5 synergistically repress cell proliferation. Mean ± s.d. of n = 3 biologically independent experiments, one-way ANOVA test. n.s. donates for no significance, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001
Register or Sign In to View Figures.

Signal transduction and targeted therapy
June 22 2022

Fig 3: DUB VCIP135 stabilizes MATIIα to promote cell proliferation by sensesing folic acid. a VCIP135 endogenously interacts with MATIIα. b VCIP135 knockdown increases MATIIα ubiquitylation. HEK293T cells were transfected with the indicated plasmids. c VCIP135 WT but not enzymatic-dead mutant C218S decreases MATIIα ubiquitylation. HEK293T cells were transfected with the indicated plasmids. d, e VCIP135 WT but not enzymatic-dead mutant stabilizes MATIIα upon folate deprivation for 72 h. MHCC-97H cells were cultured under folate-deprived condition, followed by CHX treatment. Mean ± s.d. of n = 3 (d) biologically independent experiments, one-way ANOVA test. f MG132 rescues MTX-reduced MATIIα protein level in multiple HCC cell lines. g Folate rescues MTX-reduced MATIIα protein level in MHCC-97H and Huh7 cells. h Working model. VCIP135 deubiquitylates MATIIα in response to folate and induces MATIIα accumulation in protein level. Data (a–c and e–g) are representative of three independent experiments. n.s. donates for no significance, ***P < 0.001 and ****P < 0.0001

Be the first to write a review!

Citations:

(3)

Figures:

Supplier Page

Supplier Page from
Cell Signaling Technology for
VCIP135 Antibody

The VCIP135 Antibody from Cell Signaling Technology is a Rabbit Polyclonal antibody to VCPIP1. This antibody recognizes Homo Sapiens, Human, and Non-Human Primate antigen. The VCIP135 Antibody has been validated for the following applications: Precipitation, Immunoprecipitation, and Western Blot.

Description

VCIP135 Antibody recognizes endogenous levels of total VCIP135 protein

Signal transduction and targeted therapy

Signal transduction and targeted therapy

Signal transduction and targeted therapy

VCIP135 Antibody from Cell Signaling Technology

Description

Cell Signaling Technology

Citations (3)

Reviews

VCIP135 Antibody from Cell Signaling Technology

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map